Brief: Clarity Pharmaceuticals Gets US FDA Fast Track Designation For Cu- 64 Sar-Bispsma
24/01/2025 01:28
Jan 24 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* U.S. FDA FAST TRACK DESIGNATION FOR CU- 64 SAR-BISPSMA IN
BIOCHEMICAL RECURRENCE OF PROSTATE CANCER
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial